Admedus has expanded its distribution partnership with Coroneo to sell its Extra-Aortic Annuloplasty Ring and related products in Australia and New Zealand. According to a press release, Admedus anticipates gaining marketing approval for this unique aortic implant in the second half of 2016.
“We are pleased to build on our existing partnership with Coroneo to distribute their leading aortic ring in Australia and New Zealand. This will be an extension to the current arrangement we have for the UK and Germany,” says Admedus chief executive officer, Lee Rodne.
The Coroneo Extra-Aortic Ring is specially-designed to surgically repair the aortic valve, and complements the use of CardioCel in heart valve repairs, according to the release. CardioCel was recently featured in a presentation at the Heart Valve Society meeting in New York, which discussed CardioCel’s profile with respect to native aortic valves.
In October 2015, Admedus also initiated a post-market clinical study using CardioCel to reconstruct aortic valves in 80 patients across four leading heart centres in the US and Europe. The study is designed to observe the utility and benefits which CardioCel may provide in aortic valve reconstruction over valve replacements. Patients in the clinical study will be reviewed six, 12 and 24 months post-surgery to evaluate safety data and primary and secondary endpoints.